20.12.2018 • News

Azelis to Take Italy’s Deafarma

Azelis to Take Italy’s Deafarma (c) Azelis
Azelis to Take Italy’s Deafarma (c) Azelis

Leading specialty chemicals and food ingredients distributor Azelis is in exclusive talks to acquire Deafarma, an Italian distributor of APIs.

The Milan-based company also offers a range of services such as searching for new APIs, assistance with regulatory affairs and new pharmaceutical dossier support.

Commenting on the deal, Marco Gerosa, regional managing director Italy at Azelis, said: “There is an excellent strategic fit that supports our further growth in the region, allowing us to provide an improved product offering and customer reach on one side, while making us more attractive to our existing principals on the other. Our aim is to offer our customers in Italy the full pharma range of products.”

The transaction is expected to complete in the first quarter of 2019.

Azelis noted that the acquisition illustrates the support provided by owner EQT since it took over the Belgium-based distributor together with PSP Investments earlier this year. The two funds revealed in June 2018 they were in exclusive negotiations to take over Azelis from private equity owner Apax Partners.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

most read